Stock SILF HEMOGENYX PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Hemogenyx Pharmaceuticals Plc

Equities

SILF

GB00BYX3WZ24

Delayed London S.E.
Other stock markets
 10:49:40 2024-05-15 EDT 		5-day change 1st Jan Change
1.52 GBX -2.56% Intraday chart for Hemogenyx Pharmaceuticals Plc -1.17% -33.91%
04-25 Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-29 Hemogenyx Pharmaceuticals raises money for leukaemia treatment AN

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout
AN
Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Hemogenyx Pharmaceuticals raises money for leukaemia treatment
AN
Hemogenyx shares rise on potential for CBR to treat brain diseases
AN
Hemogenyx Pharmaceuticals plc Announces CBR Brain Delivery
CI
Hemogenyx says CBR can be used intranasally to treat viral infections
AN
Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold
AN
Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T
CI
Hemogenyx Pharmaceuticals Obtains US Conditioning Patent
MT
Hemogenyx hails US patent application progress
AN
Hemogenyx Pharmaceuticals plc Announces Approval and Issuance of U.S. Conditioning Patent
CI
Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA
AN
Hemogenyx Pharmaceuticals completes process qualification run
AN
Hemogenyx Pharmaceuticals plc Announces Successful Completion of Its Process Qualification Run of the End-To-End Process for the Manufacture of HEMO-CAR-T Cells
CI
Hemogenyx Pharmaceuticals plc Announces CBR Expanded to Treatment of Cancer
CI
Hemogenyx Pharmaceuticals plc Announces Lentivirus Re-Manufacturing Completed
CI
EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens
AN
Hemogenyx Pharmaceuticals Plc Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Avingtrans buys Adaptix, TPXimpact sells Questers
AN
Hemogenyx Pharmaceuticals Jumps 19% on Fresh Investment from Prevail Partners
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SILF Stock
  4. News Hemogenyx Pharmaceuticals Plc
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW